In May 2016, at the World Health Assembly, 194 governments adopted the first-ever Global Health Sector Strategy on viral hepatitis and agreed to the first-ever global targets. The strategy includes a target to treat 8 million people for hepatitis B or C by 2020. The longer term aim is to reduce new viral hepatitis infections by 90% and to reduce the number of deaths due to viral hepatitis by 65...

In May 2016, at the World Health Assembly, 194 governments adopted the first-ever Global Health Sector Strategy on viral hepatitis and agreed to the first-ever global targets. The strategy includes a target to treat 8 million people for hepatitis B or C by 2020. The longer term aim is to reduce new viral hepatitis infections by 90% and to reduce the number of deaths due to viral hepatitis by 65...

Background The term ‘‘jaundice’’ was used as early as in the ancient Greece when Hippocrates described an illness probably corresponding to a viral hepatitis. However, it was not until the beginning of the twentieth century AU :1 when a form of hepatitis was associated to an infectious disease occurring in epidemics and the term ‘‘infectious hepatitis’’ was established. Later on in the early 19...

We studied the blood distribution of T and B cells in relation to the etiology and the course of the hepatitis process, in 61 consecutive patients with acute viral hepatitis (AVH). Patients with acute viral hepatitis B showed a significant increase in total T, active T and SmIg cells, lasting the first two weeks of disease. These alterations disappeared in patients with resolving hepatitis. SmI...

BACKGROUND & OBJECTIVE Drug induced hepatotoxicity (DIH) is an important and commonly encountered adverse effect with antituberculosis (anti-TB) treatment. Acute viral hepatitis (AVH) is an important confounding reason which clinically, biochemically and histologically mimics DIH. METHODS The contributory role of acute viral hepatitis as a confounding factor in patients with normal baseline l...

BACKGROUND  The incidence and mortality rate of hepatocellular carcinoma (HCC) are increasing in the United States. Viral hepatitis infection is a primary risk factor for HCC. This study describes the relationship between viral hepatitis and HCC in New York City (NYC). METHODS  Viral hepatitis cases reported to the NYC Department of Health from 1999-2012 were matched to HCC cases diagnosed fr...

Viral hepatitis is responsible for great health, social and economic burden both globally and in the UK. This study aimed to assess the research funding awarded to UK institutions for viral hepatitis research and the relationship of funded research to clinical and public health burden of viral hepatitis. Databases and websites were systematically searched for information on infectious disease r...

Viral hepatitis has not received the level of attention that it warrants. However, the global picture began to change in May, 2010, when the World Health Assembly adopted its fi rst resolution on viral hepatitis. Recent data clearly show the magnitude of the challenge. Hepatitis A and E together caused more than 34 million cases of illness in 2005. According to Global Burden of Disease estimate...

Acute pancreatitis is considered to be an extremely rare extrahepatic manifestation of acute viral hepatitis E. The incidence is reported to be around 5%-6% in the available case series. It has usually been reported in non-fulminant cases of acute viral hepatitis E in the second or third week of illness, with a favourable outcome. Here, we report the case of a young male subject with acute vira...

In South Korea (S. Korea), viral hepatitis is a major public health burden. Advances in healthcare policy, evidence-based medicine, and therapeutic strategies in S. Korea have brought a rapid change in the sociodemographic and clinical characteristics of viral hepatitis. This review discusses the innovative approaches that S. Korea has taken to curb the epidemic of viral hepatitis. In addition,...